Meng Jiang

Title: Meng Jiang - Innovator in Cancer Treatment

Introduction

Meng Jiang is a notable inventor based in Suzhou, China. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on the development of inhibitors that target specific pathways involved in cancer progression.

Latest Patents

Meng Jiang holds a patent for solid forms of a PARP7 inhibitor. The patent, titled "Solid forms of a PARP7 inhibitor," relates to the compound 5-[[[2S]-1-(3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy)propan-2-yl]amino]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one, and its salts. This invention is particularly relevant for its potential use in cancer treatment, providing new avenues for therapeutic intervention.

Career Highlights

Throughout his career, Meng Jiang has worked with several prominent companies in the pharmaceutical industry. Notably, he has been associated with Ribon Therapeutics, Inc. and Qilu Regor Therapeutics Inc. His experience in these organizations has allowed him to contribute to groundbreaking research and development efforts.

Collaborations

Meng Jiang has collaborated with several professionals in his field, including Melissa Marie Vasbinder and Laurie B Schenkel. These collaborations have enhanced his research capabilities and have led to significant advancements in cancer treatment methodologies.

Conclusion

Meng Jiang is a dedicated inventor whose work in developing PARP7 inhibitors represents a significant advancement in cancer therapy. His contributions to the field are invaluable, and his ongoing research continues to inspire innovation in the pharmaceutical industry.